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Abstract 
Background 
As  the  size  and  complexity  of  scientific  datasets 
and  the  corresponding  information  stores  grow, 
standards  for  collecting,  describing,  formatting, 
submitting and exchanging information are playing 
an  increasingly  active  role.  Several  initiatives 
occupy  strategic  positions  in  the  international 
scenario,  both  within  and  across  domains. 
However,  the  job  of  harmonising  reporting 
standards  is  still  very  much  a  work  in  progress; 
both  software  interoperability  and  the  data 
integration remain challenging as things stand.  
Results 
The  status  quo  with  respect  to  standardization 
initiatives  is  summarized  here,  with  particular 
emphasis on the motivation for, and the challenges 
of,  ongoing  synergistic  activities  amongst  the 
academic  community  focused  on  the  creation  of 
truly interoperable standards.  
Conclusions 
Groups  generating  standards  should  engage  with 
ongoing  cross-domain  activities  to  simplify  the 
integration  of  heterogeneous  data  sets  to  the 
greatest possible extent. 
Background 
The growing complexity of datasets 
In  the  area  of  life  science,  the  cycle  of  data 
generation  and  processing  is  being  vastly 
accelerated by the development of high-throughput 
experimental methods associated with genomic and 
post-genomic  technologies  (e.g.  genomics, 
transcriptomics,  proteomics,  and  metabolomics, 
hereafter  referred  as  ‘omics’).  Biological  and 
biomedical  studies  commonly  range  from  simple 
one  assay-based  to  complex  multi-assay  studies. 
For  the  latter  type,  for  example,  consider  the 
reporting  of  a  study  looking  at  the  effect  on  a 
number of subjects treated with different drugs by 
characterizing the metabolic profile of their urine 
(by  mass  spectroscopy),  measuring  protein  and 
gene expression in the liver (by mass spectrometry 
and  DNA  microarrays,  respectively),  and 
conducting  conventional  histological  analysis. 
Omics  studies  are  information  intensive  and  to 
record  their  complex  structure  it  is  necessary  to 
define  and  capture  the  experimental  metadata, 
including  experimental  design,  sample  source(s) 
and treatment(s), the preparation of the sample for 
the analytical assay, the processes and instruments 
used  throughout,  and  the  final  data.  It  is  widely 
recognized that capturing experimental metadata on 
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this  level  of  granularity  is  required  to  correctly 
interpret  the  results  that  they  contextualize  and 
enable efficient data sharing.  
Standardization Initiatives Focused on 
Particular Domains of Application 
Many groups have risen to this challenge; standards 
for  collecting,  describing,  formatting,  submitting 
and exchanging both the data and metadata from 
such complex studies either are under development 
or  have  been  released  [1].  Currently,  several 
standards  initiatives  occupy  strategic  positions  in 
the international scenario, largely falling into two 
groups identifiable by the needs of their respective 
user communities. 
One  group  of  initiatives  is  driven  by  regulatory 
frameworks, and often supported by accredited (de 
jure) Standards Developing Organizations (SDOs). 
Most  significantly,  these  efforts  focus  on  the 
Voluntary eXploratory Data Submissions (VXDS) 
and electronic data submission programs of the US 
Food  and  Drug  Administration  (FDA)  [2-4]  or 
around initiatives by other governmental agencies, 
such as the US Environmental Protection Agency 
(EPA)  [5].  These  initiatives  also  include  long-
standing  efforts  in  the  clinical  and  non-clinical 
domains [6] alongside more recent activities in the 
pharmacogenomics  area  that  add  complex  omics 
technologies to biomedical studies [7]. 
A second group of initiatives that address particular 
(omics or other) technologies or defined domains 
of application (e.g. system biology, pathways) have 
emerged from the academic community, in many 
cases with the support of commercial organizations 
such as instrument vendors. Such initiatives (e.g., 
[8-14])  are  focused  on  supporting  tool 
interoperability  and  data  exchange  among  public 
and proprietary  systems through  the development 
of  three  kinds  of  (de  facto)  reporting  standards: 
‘minimum  information’  checklists  (specifications 
of data set content, however encoded), ontologies 
(semantics)  and  file  formats  (syntax).  Minimal 
information checklists are easy-to-read, structured 
documents  that reflect the consensus  view of the 
essential  pieces  of  information  that  should  be 
reported; ontologies provide the semantics needed 
to describe the minimal information requirements 
and  file  formats  the  syntax  to  transmit  and 
exchange  these.  Combining  these  three  kinds  of 
reporting standards a submission tool, for example, 
should  guide  researchers  through  the  process  of 
meeting  the  reporting  requirements  made  by  a 
given  minimal  information  specification,  enable 
straightforward practical use of ontology terms and 
export  the  collected  information  in  a  standard 
format to a given database.  
Fragmentation of Standards 
Domain-specific  initiatives  are  regarded  as 
important  because  they  address  ‘real  world’  data 
reporting requirements. Unfortunately, focusing on 
particular  communities’  interests  or  technologies 
leads to duplication of effort. More seriously, the 
development  of  (largely  arbitrarily)  different 
standards  severely  hinders  data  integration. 
Nowadays  researchers  are  able  to  perform  multi-
assay studies where the same sample is run through 
the  full  range  of  ‘omics  and  conventional 
technologies, in combination. In this specific case, 
it  is  critical  that  the  reporting  standards  are 
designed to be interoperable and fit neatly into a 
jigsaw, with users being able to take the pieces that 
are relevant to report their study. The fragmentation 
severely  hinders  the  interoperability  of  databases 
and tools, implementing such reporting standards: 
this scenario is illustrated by the ArrayExpress [15] 
and PRIDE [16] – two EBI public repositories for 
transciptomics  and  proteomics  data  respectively. 
These  systems  implement  (non-interoperable) 
standards  applicable  only  for  their  ‘omics’ 
domains.  Consequently,  users  have  to  deal  with 
different  submission  formats,  diverse 
representations of the metadata and terminologies 
when depositing their datasets in these systems, and 
similarly  when  downloading  other  datasets.  Such 
fragmentation  has  a  strong  impact  on  the  user 
community,  particularly  by  hampering  deposition 
and integration of multi-assay studies. 
Results and Discussion 
Integrative  Cross-Domain  Standardization 
Initiatives 
Fortunately,  amongst  the  academic  community  a 
number  of  initiatives  aim  to  foster  the 
harmonization and consolidation of the three kinds 
of reporting standard previously described 
Content: Twenty-seven groups now participate in 
the  Minimum  Information  for  Biomedical  or 
Biological  Investigations  (MIBBI)  project,  which 
offers a one-stop shop for those exploring the range 
of extant ‘minimum information’ checklists (such 
as  MIAME  [17])  and  fosters  their  collaborative, 
integrative development [18]. 
Semantics: More than 70 groups participate in the 
Open  Biological  Ontology  (OBO)  Foundry.  The 
objective  of  the  project  is  to  encourage  the 
development  of  orthogonal,  interoperable 
ontologies [19]. 
Syntax:  Several  groups  participate  in  the 
Functional Genomics (FuGE) project to develop a 
single  generic  data  model  that  will  underpin  a 
variety of XML-based file formats by providing a 
single  common  framework  [20].  Recently,  a 
complementary  initiative  has  been  begun  by  a 
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(growing)  number  of  communities;  to 
collaboratively  develop  the 
Investigation/Study/Assay  (ISA-TAB)  a  tabular 
framework  for  presenting  experimental  metadata 
[21] that uses a reference system to complements 
existing biomedical formats such as the Study Data 
Tabulation Model (SDTM, [22]).  
These integrative cross-domain reporting standards 
are implemented by the BioInvestigation Index, a 
new prototype infrastructure at EBI set to provide 
users with a common structured representation and 
(public) storage mechanism for a variety of studies 
[23]. Although relying on EBI production systems, 
such  as  ArrayExpress  and  Pride,  the 
BioInvestigation Index shields the users from the 
diverse  reporting  standards,  by  implementing  the 
MIBBI,  OBO  Foundry  and  ISA-TAB  synergistic 
efforts in its annotation and submission tool [24]. 
Hopes and Hurdles 
To  achieve  interoperability  from  a  technical 
perspective, ‘meta’ standardization projects such as 
MIBBI,  OBO  Foundry  and  ISA-TAB  help  (i) 
resolving  overlaps  between  domain-specific 
standards and (ii) plugging gaps where they exist. It 
is anticipated, also, that some reporting standards 
will be more mature – ‘ready’ to be integrated – 
than others, particularly because development takes 
time  and  'buy-in'  both  from  potential  users  and 
those  that  govern  them  (journals,  funders, 
regulators).  These  are  technically  complex,  but 
demonstrably  tractable  tasks.  By  contrast,  the 
sociological  barriers  facing  these  kinds  of  large-
scale  collaborations  can  be  far  more  challenging, 
mandating extensive liaison between communities. 
Managing the process of consensus building from 
start to finish takes time and expertise. However, 
the time participants can dedicate to these projects 
is  chronically  limited  due  to  lack  of  financial 
support. The massively collaborative nature of such 
undertakings  requires  frequent  face-to-face 
workshops  to  create  the  necessary  conditions  for 
the  building  of  consensus.  Unfortunately,  for  the 
initiatives  that  have  emerged  from  the  academic 
community, this is difficult without central grants 
or  with  limited  funds  [25].  Despite  this  chronic 
resource limitation, the lack of standardization is so 
problematic for researchers and those that support 
them,  repeatedly  proving  to  be  a  significant 
bottleneck  in  the  collection,  sharing,  and 
integration  of  data  that  both  developers,  and  the 
potential users, continue to participate on an almost 
exclusively voluntary basis. 
Two  stakeholders  have  pivotal  roles  to  play  as 
enablers. Journals increasingly require compliance 
with  appropriate  consensual  reporting  standards, 
contingent  on  the  availability  of  appropriate 
software  and  public  repositories  [26,  27,  28]. 
Consistent reporting has a positive and long-lasting 
impact on the value of collective scientific outputs. 
This has also been recognized by funding agencies 
that are increasingly playing an active role in the 
strategic stewardship of omics data, often through 
the development of data policies encouraging the 
use  of  (existing)  standards  and  public  standards-
compliant  repositories  for  data  collection  and 
management [29]. 
Conclusions 
This paper has illustrated the growing number of 
standards  and  the  complexity  facing  those 
attempting to use them, for example, to report or 
integrate datasets from multiple domains. We have 
also  indicated  the  existence  of  a  number  of 
synergistic projects seeking to simplify the process 
of integrating reporting standards, where possible. 
Of  course,  this  is  not  an  exhaustive  list;  several 
coordinative  infrastructure  initiatives  work  to 
address the problem of sharing and archiving large 
amounts of data, according to common  standards 
(e.g., [30-32]). 
There  are  many  benefits  accruing  to  the 
development and acceptance of reporting standards. 
For example, by limiting the range and variability 
of  standards,  the  development  and  maintenance 
costs  for  commercial  and  academic  software 
developers of standards-compliant products comes 
down.  This  results  in  more  appropriate  resources 
for  the  biomedical  and  scientific  community, 
making  the  job  of  capturing,  annotating, 
integrating,  sharing  and  exploiting  (meta)data 
simpler,  increasing  the  prima  facie  value  of  the 
data to others (secondary users), and by extension, 
increasing the return on the investment of (public) 
funds that supported their generation.  
Above  all  actions  a  ‘top-down’  coordination  is 
needed  to  help  bringing  these  standardization 
efforts  closer  to  address  the  fragmentation  issue. 
Although,  regulatory-  or  biomedical-driven 
initiatives  have  far  stricter  guidelines  than 
academia, much could be learned from exchange of 
ideas and practices of these sectors. 
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